Form 4: CNS Pharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
Rami Levin, CEO and President of CNS Pharmaceuticals, Inc., reported multiple transactions in common stock on August 14, 2026.
Summary
- Option exercise/conversion: disposed of 4,750 Common Stock on August 14, 2026; holds 4,750 after (Direct).
- Option exercise/conversion: disposed of 4,750 Restricted Stock Units on August 14, 2026; holds 14,250 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rami Levin — Officer (CEO and President)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-14 | Option exercise/conversion | Common Stock | 4,750 | — | — | 4,750 |
| 2026-08-14 | Option exercise/conversion | Restricted Stock Units | 4,750 | — | — | 14,250 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-14 | Option exercise/conversion (4,750 shares) |
| 2026-08-14 | Option exercise/conversion (4,750 shares) |
Keywords
insider transaction, Form 4, CNSP, CNS Pharmaceuticals, Inc., neutral, Rami Levin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.